Beckman Coulter Features Prostate Health Index (phi) at 2015 AUA Annual Meeting

Beckman Coulter Diagnostics, a leader in prostate cancer testing, will demonstrate its dedication to advancing healthcare for patients and physicians at the 2015 American Urological Association (AUA) Annual Meeting in New Orleans, LA, May 15–19, 2015.

The Beckman Coulter exhibition booth (#2623) will showcase the company’s Prostate Health Index (phi)* — the solution for better prostate cancer detection. The Prostate Health Index is:

• A simple blood test that is three times more specific for the detection of prostate cancer than PSA alone¹
• The only multi-analyte PCa blood test with FDA approval²
• The only multi-analyte blood test recommended in the National Comprehensive Cancer Network Guidelines (NCCN) for PCa Early Detection

A patient’s phi score gives more accurate information about what an elevated PSA level might mean and the probability of finding prostate cancer on biopsy. Beckman Coulter’s phi test fills the diagnostic gap between PSA screening and a prostate biopsy.

The phi test is now more broadly available to physicians nationwide through Physician’s Choice Laboratory Services (PCLS). PCLS is an emerging esoteric laboratory focused on helping providers manage complex disease states in urologic health, women’s health, heart health, and toxicology. PCLS has added Beckman Coulter’s phi to its advanced diagnostics menu and has initiated a commercial roll-out of this ground-breaking test across the United States. Learn more at ProstateHealthIndex.org.

In addition to the exhibition booth, Beckman Coulter is hosting the following events at the AUA Annual Meeting:

Industry Clinical Update (ICU) Theater:
“The Prostate Health Index: New Evidence & Experience in Clinical Practice”
William Catalona, MD, Kevin Slawin, MD, and Stacy Loeb, MD
Saturday, May 16, 2015 | 11 a.m. – 12 p.m.
Science and Technology Hall: Booth #1043

Poster Presentations:
Prostate Health Index Predicts Upgrading of Men on 5-alpha Reductase Inhibitors
Abstract ID: MP6-06
E. David Crawford, et al.
Friday, May 15, 2015 | 1 p.m. – 3 p.m.
NOMCC: Room 220-221

Prostate Health Index Is an Effective Marker for Risk Stratification of Prostate Cancer Patients
Abstract ID: MP60-08
E. David Crawford, et al.
Monday, May 18, 2015 | 8 a.m. – 10 a.m.
NOMCC: Room 206-207

Multicenter Evaluation of the Prostate Health Index (phi) for Detection of Aggressive Prostate Cancer in Biopsy-Naïve Men
Abstract ID: PD46-02
Claire de la Calle, et al.
Monday, May 18, 2015 | 3:30 p.m. – 5:30 p.m.
NOMCC: Room 215-216

Industry Expert Event:
Meet a phi Expert, Kevin Slawin, MD, at Booth #2623
Sunday, May 17, 2015 | 2 p.m. – 3 p.m.
Monday, May 18, 2015 | 10 a.m. – 11 a.m.

Visitors to Beckman Coulter’s booth will have opportunities to learn from industry experts how the company’s latest diagnostic prostate cancer innovation is enabling physicians with better knowledge and greater confidence in patient care.

¹Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate-specific antigen combined with prostate-specific antigen and free prostate-specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/mL prostate-specific antigen range. J Urology 2011 May;185:1650-55.

²phi is a combination of three Beckman Coulter assays: Access Hybritech PSA, Access Hybritech free PSA, and Access Hybritech p2PSA.